6th Jul 2016 15:58
Abzena plc
Block Listing Update
Cambridge, UK, 6 July 2016 - Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 5 January 2016, the Group announces that a total of 930,527 ordinary shares of £0.002 each in the share capital of the Group ('Ordinary Shares') have been issued since that date pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below.
The Group holds no shares in treasury and hence the total number of current voting rights is 137,055,555. The Group will notify on a monthly basis when there are changes to the issued share capital, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Group.
BLOCK LISTING SIX MONTHLY RETURN
Name of applicant: | Abzena plc | |||
Name of scheme: | Abzena plc 2013 Share Incentive Plan | |||
Period of return: | From: | 5 January 2016 | To: | 5 July 2016 |
Balance of unallotted securities under scheme(s) from previous return: | 1,763,003 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 930,527 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period | 832,476 | |||
Number and class of securities originally admitted and the date of admission | [1,779,000 ordinary shares of £0.002 each, admitted on 13 July 2015] | |||
Name of contact: | Julian Smith | |||
Telephone number of contact: | +44 1223 903 498 | |||
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498 |
Cenkos Securities (Nominated Adviser and Broker) Christopher Golden / Ivonne Cantu
| +44 20 7397 8900 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne Sewell / Rozi Morris
| +44 20 7457 2020 |
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
§ Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
§ Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
§ Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
§ Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com
Related Shares:
Abzena